Uy Ear
Stock Analyst at Mizuho
(1.02)
# 1628
Out of 5,270 analysts
67
Total ratings
30.77%
Success rate
11.64%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Arcutis Biotherapeut... | Maintains: Outperform | 20 21 | 12.79 | 64.19% | 14 | Feb 26, 2025 | |
uniQure | Maintains: Neutral | 7 20 | 10.89 | 83.65% | 4 | Dec 19, 2024 | |
Relmada Therapeutics | Downgrades: Neutral | 23 1 | 0.26 | 284.62% | 1 | Dec 5, 2024 | |
Alkermes | Maintains: Outperform | 35 40 | 34.1 | 17.3% | 5 | Nov 13, 2024 | |
Sage Therapeutics | Maintains: Neutral | 18 16 | 7.21 | 121.91% | 2 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 40 | 17.58 | 127.53% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 145 179 | 101.19 | 76.89% | 5 | May 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 25 21 | 18.14 | 15.77% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 20 23 | 14.35 | 60.28% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 116 140 | 114.47 | 22.3% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 60 24 | n/a | n/a | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 35 16 | n/a | n/a | 1 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 3 | n/a | n/a | 2 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 36 40 | 167.03 | -76.05% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 2 | n/a | n/a | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 10 | 1.68 | 495.24% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 5 3 | 0.6 | 400% | 2 | Mar 1, 2023 |